OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Mukhtar, Ebtihal A; Gadalla, Nahla B; El-zaki, Salah-Eldin G; Mukhtar, Izdihar; Mansour, Fathi A; Babiker, Ahmed; El-Sayed, Badria B (2007)
Publisher: BioMed Central
Journal: Malaria Journal
Languages: English
Types: Article
Subjects: RC955-962, RC109-216, Infectious Diseases, Infectious and parasitic diseases, Arctic medicine. Tropical medicine, Research, Parasitology

Classified by OpenAIRE into

mesheuropmc: parasitic diseases



A combination of artesunate (AS) plus sulphadoxine/pyrimethamine (SP) as first-line and artemether-lumefantrine (AL) as second-line treatment are currently recommended against uncomplicated P. falciparum infection in Sudan. However, there is limited information on the efficacy of ACTs in the country and only one report of PCR-corrected results for AS/SP only.


The WHO protocol for the assessment of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria was employed. Artesunate plus sulphadoxine/pyrimethamine (AS/SP) was compared to artemether-lumefantrine (AL) in a 28-day follow up. Samples that were classified as early treatment failure (ETF), late treatment failure (LCF) or late parasitological failure (LPF) were genotyped for msp-1 and msp-2 genes to differentiate recrudescence from reinfection.


A total of 178 patients were screened and 160 met the enrolment criteria and were recruited to the study of which 157 (98.1%) completed the follow up and had an analysed treatment outcome. On the AS/SP arm, three (0.038%) patients were lost during the follow-up, two on day 1 and one on day 7, and 77 (96.3) completed the study, while all 80 (100%) patients completed the follow up in the AL arm. In the per protocol analysis for AS/SP the treatment outcome for patients who completed the follow-up were as follows: adequate clinical and parasitological response (ACPR); 84.4% ETF; 1.3%, LCF; 3.9%, (LPF); 10.4%. For the AL arm the out come was as follows, ACPR; 90%, ETF; 0%, LCF; 6.3% and LPF; 3.8%. However, when PCR-corrected, 6.5% (5/77) of patients treated with AS/SP maintained parasites from their primary infection, while (7/80) in the AL group maintained their initial parasite genotype. Therefore, PCR-corrected efficacy was 93.5% in the AS/SP treated group and for AL it was 91.3%.


Both AS/SP and AL are highly effective for the treatment of uncomplicated falciparum malaria in eastern Sudan. However, AS/SP appears to have a slightly higher efficacy than AL, this may be due to patient compliance with the repeated dose rather than drug efficacy.

  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Malik EM O.M., Khalafalla: Malaria in Sudan: past, present and the future. Gezira Journal of Health Sciences 2004, 1( Supplement):47-51.
    • 2. Babiker HA, Pringle SJ, Abdel-Muhsin A, Mackinnon M, Hunt P, Walliker D: High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcrt and the multidrug resistance Gene pfmdr1. J Infect Dis 2001, 183(10):1535-1538.
    • 3. Adam I EMI: Resistance of P. falciparum to antimalarial drugs in Sudan. Khartoum Med J 2005.
    • 4. Salah MT, Mohammed MM, Himeidan YE, Malik EM, Elbashir MI, Adam I: A randomized comparison of sulphadoxine-pyrimethamine and combination of sulphadoxine pyrimethamine with chloroquine in the treatment of uncomplicated falciparum malaria in Eastern Sudan. Saudi Med J 2005, 26(1):147-148.
    • 5. Malik EM, Mohamed TA, Elmardi KA, Mowien RM, Elhassan AH, Elamin SB, Mannan AA, Ahmed ES: From chloroquine to artemisinin-based combination therapy: the Sudanese experience. Malar J 2006, 5:65.
    • 6. Adam I, Ali DM, Abdalla MA: Artesunate plus sulfadoxinepyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan. Trans R Soc Trop Med Hyg 2006, 100(7):632-635.
    • 7. Elamin SB, Malik EM, Abdelgadir T, Khamiss AH, Mohammed MM, Ahmed ES, Adam I: Artesunate plus sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan. Malar J 2005, 4:41.
    • 8. Mohamed AO, Eltaib EH, Ahmed OA, Elamin SB, Malik EM: The efficacies of artesunate-sulfadoxine-pyrimethamine and artemether-lumefantrine in the treatment of uncomplicated, Plasmodium falciparum malaria, in an area of low transmission in central Sudan. Ann Trop Med Parasitol 2006, 100(1):5-10.
    • 9. Ibrahium AM, Kheir MM, Osman ME, Khalil IF, Alifrangis M, Elmardi KA, Malik EM, Adam I: Efficacies of artesunate plus either sulfadoxinepyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. Annals of Tropical Medicine and Parasitology 2007, 101:15-21.
    • 10. WHO: Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated malaria. 2003.
    • 11. WHO: Excel sheet for Resistance Data Collection and analysis . [ resistance_datacollection.xls].
    • 12. Cavanagh DR, Elhassan IM, Roper C, Robinson VJ, Giha H, Holder AA, Hviid L, Theander TG, Arnot DE, McBride JS: A Longitudinal Study of Type-Specific Antibody Responses to Plasmodium falciparum Merozoite Surface Protein-1 in an Area of Unstable Malaria in Sudan. J Immunol 1998, 161(1):347-359.
    • 13. Ntoumi F, Contamin H, Rogier C, Bonnefoy S, Trape JF, MercereauPuijalon O: Age-dependent carriage of multiple Plasmodium falciparum merozoite surface antigen-2 alleles in asymptomatic malaria infections. Am J Trop Med Hyg 1995, 52(1):81-88.
    • 14. Zwetyenga J, Rogier C, Tall A, Fontenille D, Snounou G, Trape JF, Mercereau-Puijalon O: No influence of age on infection complexity and allelic distribution in Plasmodium falciparum infections in Ndiop, a Senegalese village with seasonal, mesoendemic malaria. Am J Trop Med Hyg 1998, 59(5):726-735.
    • 15. Terkuile F, White NJ, Holloway P, Pasvol G, Krishna S: Plasmodium falciparum: In Vitro Studies of the Pharmacodynamic Properties of Drugs Used for the Treatment of Severe Malaria. Experimental Parasitology 1993, 76(1):85-95.
    • 16. Tagelsir N, Ibrahim Z, Medani A, Salih O, Hamad A, Giha H, El-Agib A, Khan B, Saeed N, Ibrahim M: High frequency of Plasmodium falciparum PfCRT K76T and PfpghN86Y in patients clearing infection after chloroquine treatment in the Sudan. Acta Trop 2006, 97(1):19-25.
    • 17. Adam I, IE AE, Idris SM, Malik EM, Elbashir MI: A comparison of the efficacy of artesunate plus sulfadoxine-pyrimethamine with that of sulfadoxine-pyrimethamine alone, in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. Ann Trop Med Parasitol 2005, 99(5):449-455.
    • 18. Abdel-Muhsin AM, Mackinnon MJ, Ali E, Nassir el KA, Suleiman S, Ahmed S, Walliker D, Babiker HA: Evolution of drug-resistance genes in Plasmodium falciparum in an area of seasonal malaria transmission in Eastern Sudan. J Infect Dis 2004, 189(7):1239-1244.
    • 19. Gadalla N Salah Eldin Elzaki, Ebtihal Mukhtar, Fathi Mansour, Izdihar Mukhtar, Amal Gadalla, Ahmed Babiker, Badria B. El Sayed: The Impact of clearing asymptomatic Plasmodium falciparum parasitaemia on drug resistance genes in an area of seasonal transmission in Sudan. In International Conference for Parasitology, ICOPA Glasgow, U.K. ; 2006.
    • 20. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G: Selection of Plasmodium falciparum pfmdr1 Alleles following Therapy with Artemether-Lumefantrine in an Area of Uganda where Malaria Is Highly Endemic. Antimicrob Agents Chemother 2006, 50(5):1893-1895.
    • 21. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, Sutherland CJ, Hallett RL: Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother 2007, 51(3):991-997.
    • 22. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP: In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 2005, 191(6):1014-1017.
    • 23. Hastings IM, Watkins WM: Tolerance is the key to understanding antimalarial drug resistance. Trends in Parasitology 2006, 22(2):71-77.
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok